These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 23606682

  • 1. A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.
    den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, Raterman H, van Schaardenburg D, van Dillen N, Dijkmans B, Lems W.
    Ann Rheum Dis; 2014 Jun; 73(6):1071-8. PubMed ID: 23606682
    [Abstract] [Full Text] [Related]

  • 2. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
    ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D, Voskuyl AE, Lems WF.
    Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633
    [Abstract] [Full Text] [Related]

  • 3. Is attenuated COBRA treatment strategy (COBRA-light) non-inferior or not non-inferior than original COBRA strategy?
    Akar S, Tinazli M.
    Clin Exp Rheumatol; 2014 Jun; 32(6 Suppl 87):S-18. PubMed ID: 25327510
    [No Abstract] [Full Text] [Related]

  • 4. Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial.
    Lucassen MJJ, Ter Wee MM, den Uyl D, Konijn NPC, Nurmohamed MT, Voskuyl AE, van Schaardenburg D, Kerstens PJSM, Bultink IEM, Boers M, Lems WF.
    Osteoporos Int; 2021 Jul; 32(7):1441-1449. PubMed ID: 33464392
    [Abstract] [Full Text] [Related]

  • 5. Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis.
    Rasch LA, van Tuyl LH, Lems WF, Boers M.
    Neuroimmunomodulation; 2015 Jul; 22(1-2):51-6. PubMed ID: 25227967
    [Abstract] [Full Text] [Related]

  • 6. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 7. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
    Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.
    Rheumatology (Oxford); 2017 Sep 01; 56(9):1586-1596. PubMed ID: 28859326
    [Abstract] [Full Text] [Related]

  • 8. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
    Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, van Denderen JC, Westedt ML, Peeters AJ, Dijkmans BA, Jacobs P, Boonen A, van der Heijde DM, van der Linden S.
    Arthritis Rheum; 2002 Feb 01; 46(2):347-56. PubMed ID: 11840436
    [Abstract] [Full Text] [Related]

  • 9. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
    Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R, NORD-STAR study group.
    BMJ; 2020 Dec 02; 371():m4328. PubMed ID: 33268527
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis.
    Boers M, van Tuyl L, van den Broek M, Kostense PJ, Allaart CF.
    Ann Rheum Dis; 2013 Mar 02; 72(3):406-9. PubMed ID: 23155223
    [Abstract] [Full Text] [Related]

  • 11. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I, Van Tulder M, Boers M, Verhoeven AC, Adèr HJ, Bibo J, Boonen A, Van Der Linden S.
    J Rheumatol; 2004 Sep 02; 31(9):1709-16. PubMed ID: 15338488
    [Abstract] [Full Text] [Related]

  • 12. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S.
    Lancet; 1997 Aug 02; 350(9074):309-18. PubMed ID: 9251634
    [Abstract] [Full Text] [Related]

  • 13. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
    van Tuyl LH, Lems WF, Voskuyl AE, Kerstens PJ, Garnero P, Dijkmans BA, Boers M.
    Ann Rheum Dis; 2008 Nov 02; 67(11):1574-7. PubMed ID: 18625629
    [Abstract] [Full Text] [Related]

  • 14. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, Bijkerk C, Speyer I, de Buck MP, de Sonnaville PB, Grillet BA, Huizinga TW, Allaart CF.
    Ann Rheum Dis; 2014 Jul 02; 73(7):1356-61. PubMed ID: 23716067
    [Abstract] [Full Text] [Related]

  • 15. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
    van Tuyl LH, Boers M, Lems WF, Landewé RB, Han H, van der Linden S, van de Laar M, Westhovens R, van Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huizinga TW, van de Brink H, Dijkmans BA, Voskuyl AE.
    Ann Rheum Dis; 2010 May 02; 69(5):807-12. PubMed ID: 19451137
    [Abstract] [Full Text] [Related]

  • 16. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?
    van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Dijkmans BA, Boers M.
    Ann Rheum Dis; 2007 Jul 02; 66(7):974-6. PubMed ID: 17392349
    [Abstract] [Full Text] [Related]

  • 17. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
    Poppelaars PBM, van Tuyl LHD, Boers M.
    Ann Rheum Dis; 2019 May 02; 78(5):586-589. PubMed ID: 30808623
    [Abstract] [Full Text] [Related]

  • 18. Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study.
    van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Kerstens PJ, Dijkmans BA, Boers M.
    J Rheumatol; 2009 Jul 02; 36(7):1380-6. PubMed ID: 19487259
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
    Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T, NEO-RACo Study Group.
    Ann Rheum Dis; 2013 Jun 02; 72(6):851-7. PubMed ID: 22753402
    [Abstract] [Full Text] [Related]

  • 20. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
    Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T.
    Clin Exp Rheumatol; 2012 Jun 02; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.